

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No.    )\*

---

### HOMOLOGY MEDICINES, INC.

(Name of Issuer)

Common Stock, par value \$0.0001 per share  
(Title of Class of Securities)

438083 107  
(CUSIP Number)

April 2, 2018  
(Date of Event which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1	NAME OF REPORTING PERSON  Temasek Holdings (Private) Limited		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Republic of Singapore		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER  0 shares	
	6	SHARED VOTING POWER  3,220,293 shares	
	7	SOLE DISPOSITIVE POWER  0 shares	
	8	SHARED DISPOSITIVE POWER  3,220,293 shares	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,220,293 shares		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  8.6%*		
12	TYPE OF REPORTING PERSON  HC		

\* Based on 37,430,819 shares of common stock, par value \$0.0001 per share, outstanding as of April 2, 2018, as reported in the prospectus filed by Homology Medicines, Inc. on March 29, 2018.

1	NAME OF REPORTING PERSON  Fullerton Management Pte Ltd		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Republic of Singapore		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER  0 shares	
	6	SHARED VOTING POWER  3,220,293 shares	
	7	SOLE DISPOSITIVE POWER  0 shares	
	8	SHARED DISPOSITIVE POWER  3,220,293 shares	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,220,293 shares		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  8.6%*		
12	TYPE OF REPORTING PERSON  HC		

\* Based on 37,430,819 shares of common stock, par value \$0.0001 per share, outstanding as of April 2, 2018, as reported in the prospectus filed by Homology Medicines, Inc. on March 29, 2018.

1	NAME OF REPORTING PERSON  Temasek Life Sciences Private Limited		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Republic of Singapore		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER  0 shares	
	6	SHARED VOTING POWER  3,220,293 shares	
	7	SOLE DISPOSITIVE POWER  0 shares	
	8	SHARED DISPOSITIVE POWER  3,220,293 shares	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,220,293 shares		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  8.6%*		
12	TYPE OF REPORTING PERSON  HC		

\* Based on 37,430,819 shares of common stock, par value \$0.0001 per share, outstanding as of April 2, 2018, as reported in the prospectus filed by Homology Medicines, Inc. on March 29, 2018.

1	NAME OF REPORTING PERSON  V-Sciences Investments Pte Ltd		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Republic of Singapore		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER  0 shares	
	6	SHARED VOTING POWER  625,000 shares	
	7	SOLE DISPOSITIVE POWER  0 shares	
	8	SHARED DISPOSITIVE POWER  625,000 shares	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  625,000 shares		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  1.7%†		
12	TYPE OF REPORTING PERSON  CO		

† Based on 37,430,819 shares of common stock, par value \$0.0001 per share, outstanding as of April 2, 2018, as reported in the prospectus filed by Homology Medicines, Inc. on March 29, 2018.

1	NAME OF REPORTING PERSON  TLS Beta Pte. Ltd.		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Republic of Singapore		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER  0 shares	
	6	SHARED VOTING POWER  2,595,293 shares	
	7	SOLE DISPOSITIVE POWER  0 shares	
	8	SHARED DISPOSITIVE POWER  2,595,293 shares	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  2,595,293 shares		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  <input type="checkbox"/>		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  6.9%‡		
12	TYPE OF REPORTING PERSON  CO		

‡ Based on 37,430,819 shares of common stock, par value \$0.0001 per share, outstanding as of April 2, 2018, as reported in the prospectus filed by Homology Medicines, Inc. on March 29, 2018.

**Item 1(a). Name of Issuer**

Homology Medicines, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices**

45 Wiggins Avenue, Bedford, Massachusetts 01730.

**Item 2(a). Name of Person Filing**

This Schedule 13G is being jointly filed by the following reporting persons (each a "**Reporting Person**" and collectively, the "**Reporting Persons**"):

- (i) Temasek Holdings (Private) Limited ("**Temasek**");
- (ii) Fullerton Management Pte Ltd ("**FMPL**");
- (iii) Temasek Life Sciences Private Limited ("**TLS**");
- (iv) V-Sciences Investments Pte Ltd ("**V-Sciences**"); and
- (v) TLS Beta Pte. Ltd. ("**TLS Beta**").

**Item 2(b). Address of Principal Business Office or, if None, Residence**

The address of the principal business office of each Reporting Person is 60B Orchard Road, #06-18 Tower 2, The Atrium@Orchard, Singapore 238891

**Item 2(c). Citizenship**

The citizenship of all Reporting Persons is the Republic of Singapore.

**Item 2(d). Title of Class of Securities**

Common Stock, par value \$0.0001 per share.

**Item 2(e). CUSIP Number**

438083 107

**Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

**Item 4. Ownership**

(a) Amount beneficially owned:

(i) V-Sciences directly owns 625,000 shares of Issuer's Common Stock. V-Sciences is a wholly owned subsidiary of TLS, which is a wholly owned subsidiary of FMPL, which is a wholly owned subsidiary of Temasek. Each of TLS, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

(ii) TLS Beta directly owns 2,595,293 shares of Issuer's Common Stock. TLS Beta is a wholly owned subsidiary of TLS, which is a wholly owned subsidiary of FMPL, which is a wholly owned subsidiary of Temasek. Each of TLS, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by TLS Beta.

(b) Percent of class:

See Row 11 of the cover page for each Reporting Person.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote See Row 5 of the cover page for each Reporting Person.

(ii) Shares power to vote or to direct the vote See Row 6 of the cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of See Row 7 of the cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of See Row 8 of the cover page for each Reporting Person.

**Item 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.**

The response to Item 4(a) is incorporated herein by reference.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.



**Item 10. Certifications.**

By signing below, each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 11, 2018

Temasek Holdings (Private) Limited  
By: /s/ Christina Choo, Authorized Signatory

Fullerton Management Pte Ltd  
By: /s/ Cheong Kok Tim, Director

Temasek Life Sciences Private Limited  
By: /s/ Lim Siew Lee Sherlyn, Director

V-Sciences Investments Pte Ltd  
By: /s/ Christina Choo, Director

TLS Beta Pte. Ltd.  
By: /s/ Christina Choo, Director

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Joint Filing Agreement by Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd, Temasek Life Sciences Private Limited, V-Sciences Investments Pte Ltd and TLS Beta Pte. Ltd., dated as of April 11, 2018.

**JOINT FILING AGREEMENT**

This joint filing agreement (this “**Agreement**”) is made and entered into as of April 11, 2018, by and among Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd, Temasek Life Sciences Private Limited, V-Sciences Investments Pte Ltd and TLS Beta Pte. Ltd.

The parties to this Agreement agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Form 3, Form 4, Form 5, Schedule 13D or Schedule 13G, and any and all amendments thereto, and any other document relating thereto required to be filed by them pursuant to the Securities Exchange Act of 1934, as amended.

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth above.

**TEMASEK HOLDINGS (PRIVATE) LIMITED**

By: /s/ Christina Choo  
 Name: Christina Choo  
 Title: Authorized Signatory

**FULLERTON MANAGEMENT PTE LTD**

By: /s/ Cheong Kok Tim  
 Name: Cheong Kok Tim  
 Title: Director

**TEMASEK LIFE SCIENCES PRIVATE LIMITED**

By: /s/ Lim Siew Lee Sherlyn  
 Name: Lim Siew Lee Sherlyn  
 Title: Director

**V-SCIENCES INVESTMENTS PTE LTD**

By: /s/ Christina Choo  
 Name: Christina Choo  
 Title: Director

**TLS BETA PTE. LTD.**

By: /s/ Christina Choo  
 Name: Christina Choo  
 Title: Director